Niepubliczny Zaklad Opieki Zdrowotnej Twoje Zdrowie El Sp. z o.o.

Elblag 14 trials 3 recruiting

14 Registered trials

3 Currently recruiting

Organisation

Niepubliczny Zaklad Opieki Zdrowotnej Twoje Zdrowie El Sp. z o.o.

Location

Elblag, Poland

Identifier

ORG-100043622

Address

Ul. Robotnicza 79, 82-300, Poland

Departments

3017:Poradnia Kardiologiczna
Gastroenterology
N/A
NA
NZOZ Twoje Zdrowie EL Sp. z o. o.
Poradnia gastroenterologiczna
Poradnia Hepatologiczna
Poradnia Kardiologiczna
Ul. Elizy Orzeszkowej 13

Clinical trials at this site (14)

Search interface

A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovasc… Unknown

2022-502779-40-99 Primary prevention of atherosclerotic cardiovascular di 5
HF-POLARIS: A research study to look at how well NNC0487-0111 works compared to placebo in people with heart failure and obesity Recruiting

2025-523717-29-00 HFpEF or HFmrEF and obesity 5 2026-04-28
Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease ( ATTAIN-PAD ) Recruiting

2025-523283-21-00 Peripheral Arterial Disease 5 2026-02-17
A Long-Term Study of Elafibranor in Adult Participants with Primary Biliary Cholangitis (ELFIDENCE) Recruiting

2023-505251-43-00 Primary Biliary Cholangitis 5 2024-02-28
Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a) ( MOVE-Lp(a) ) Ended

2025-521067-13-00 Atherosclerotic Cardiovascular Disease (ASCVD) 5 2026-04-24
A Study of Lepodisiran (LY3819469) in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) Ended

2023-509190-23-00 Atherosclerotic Cardiovascular Disease Elevated lp(a) 5 2024-09-03
A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovasc… Ended

2022-502779-40-00 Primary prevention of atherosclerotic cardiovascular di 5 2023-09-04
A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn’s Disease (VIVID-2) Ended

2022-502841-91-00 Crohn’s Disease 5 2020-08-12
A Phase 1b, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Safety, Engraftment, and Initial Signs of Clinical Activity of MB… Ended

2023-507376-50-00 Ulcerative Colitis 1 2024-09-27
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) Ended

2022-502899-23-00 Hepatic Encephalopathy (OHE) 5 2024-04-23
Long-term Safety and Efficacy of Efavaleukin Alfa in Subjects With Moderately to Severely Active Ulcerative Colitis Ended

2023-506046-24-00 Ulcerative Colitis (UC) 4 2023-07-03
A Phase 1b, 2-part, placebo-controlled study to evaluate the efficacy, safety, and PK of PF-07054894 in participants with mild to severe UC. Ended

2022-501047-32-00 ULCERATIVE COLITIS 3 2023-05-30
Clinical study to show if Naronapride tablets are safe and efficient for treatment of delayed stomach emptying and to find the optimal dose. Ended

2023-510195-31-00 Idiopathic or Diabetic Gastroparesis 4 2023-01-03
Safety and Efficacy of Efavaleukin Alfa in Subjects with Moderately to Severely Active Ulcerative Colitis Ended

2023-506004-93-00 Ulcerative Colitis (UC) 4 2022-03-01